Background The Allergy Patient Identification for Immunotherapy (AsPIRe) program was a parallel physician and patient survey. The objectives were to examine physician and patient perceptions of seasonal allergy symptoms and their impact on patients, and to examine patient and physician attitudes to allergen immunotherapy (AIT) for seasonal allergies. AsPIRe was led by a steering committee and received research ethics board clearance from Queen's University. Methods Allergists (17) from across Canada enrolled in the AsPIRe program and completed an on-line survey to collect demographic information and baseline perceptions. Allergists then recruited patients and completed paper-based parallel physician and patient questionnaires. Patients received an AIT informational booklet with their questionnaire. Patients who were AIT-naïve with no contraindication to AIT and 12 years of age and older met the inclusion criteria. Results The survey was in field from February 2018 to June 2018. A total of 141 allergist surveys and 136 patient surveys were completed. Mean age of patients was 30 years old (range 12-70). Fifty-seven percent of patients reported prior knowledge of AIT. Seventy-two percent of patients reported seasonal allergies of longer than 5 years duration and in this subset of patients, 46% were at their first allergist visit. Seventy-three percent of all patients indicated they would be likely or very likely to try sublingual immunotherapy (SLIT), if recommended by their allergist compared to 36% for subcutaneous immunotherapy (SCIT). Conversely, 10% of patients reported they would be unlikely or very unlikely to try SLIT compared to 46% of patients who would be unlikely or very unlikely to try SCIT if recommended by their allergist. Conclusions In this particular study cohort, there was a gap in perception between allergists and their patients as to the impact of allergy symptoms on daily life. Patients reported being more frequently impacted vs. their physician's assessment. When asked about preference for AIT options, Canadian patients reported they were more likely to follow their allergists' recommendation for initiation of SLIT compared to SCIT.

中文翻译：

---

患者和医生对季节性过敏性鼻炎和过敏原免疫治疗的看法：一项平行的医生患者调查。

背景 免疫治疗过敏患者识别 (AsPIRe) 计划是一项平行的医生和患者调查。目的是检查医生和患者对季节性过敏症状的看法及其对患者的影响，并检查患者和医生对季节性过敏的过敏原免疫疗法 (AIT) 的态度。AsPIRe 由一个指导委员会领导，并获得了皇后大学研究伦理委员会的批准。方法 来自加拿大各地的过敏症患者 (17) 参加了 AsPIRe 计划并完成了一项在线调查，以收集人口统计信息和基线认知。过敏症专家随后招募了患者并完成了基于纸质的平行医生和患者问卷。患者收到一份 AIT 信息手册及其问卷。未接受过 AIT 且无 AIT 禁忌症且年龄在 12 岁及以上的患者符合纳入标准。结果调查于2018年2月至2018年6月进行，共完成141名过敏者调查和136名患者调查。患者的平均年龄为 30 岁（范围 12-70）。57% 的患者报告了 AIT 的先验知识。72% 的患者报告了持续时间超过 5 年的季节性过敏，而在这部分患者中，46% 的患者是首次就诊时过敏。73% 的患者表示，如果过敏专科医生推荐，他们可能或非常可能尝试舌下免疫疗法 (SLIT)，而皮下免疫疗法 (SCIT) 的这一比例为 36%。反过来，10% 的患者报告说他们不太可能或非常不可能尝试 SLIT，相比之下，如果过敏症专家推荐，46% 的患者不太可能或非常不可能尝试 SCIT。结论 在这个特定的研究队列中，过敏症专家和他们的患者在过敏症状对日常生活的影响方面存在差距。与医生的评估相比，患者报告受到的影响更频繁。当被问及对 AIT 选择的偏好时，加拿大患者报告说，与 SCIT 相比，他们更有可能遵循过敏症专家对 SLIT 的建议。对于过敏症状对日常生活的影响，过敏症专家和他们的患者之间存在差距。与医生的评估相比，患者报告受到的影响更频繁。当被问及对 AIT 选择的偏好时，加拿大患者报告说，与 SCIT 相比，他们更有可能遵循过敏症专家对 SLIT 的建议。对于过敏症状对日常生活的影响，过敏症专家和他们的患者之间存在差距。与医生的评估相比，患者报告受到的影响更频繁。当被问及对 AIT 选择的偏好时，加拿大患者报告说，与 SCIT 相比，他们更有可能遵循过敏症专家对 SLIT 的建议。